BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guh AY, Mu Y, Winston LG, Johnston H, Olson D, Farley MM, Wilson LE, Holzbauer SM, Phipps EC, Dumyati GK, Beldavs ZG, Kainer MA, Karlsson M, Gerding DN, McDonald LC; Emerging Infections Program Clostridioides difficile Infection Working Group. Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. N Engl J Med 2020;382:1320-30. [PMID: 32242357 DOI: 10.1056/NEJMoa1910215] [Cited by in Crossref: 132] [Cited by in F6Publishing: 65] [Article Influence: 66.0] [Reference Citation Analysis]
Number Citing Articles
1 Hernandez BG, Vinithakumari AA, Sponseller B, Tangudu C, Mooyottu S. Prevalence, Colonization, Epidemiology, and Public Health Significance of Clostridioides difficile in Companion Animals. Front Vet Sci 2020;7:512551. [PMID: 33062657 DOI: 10.3389/fvets.2020.512551] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chen J, Du Y, Lu Y, Wang H, Wu Q. Recent development of small-molecular inhibitors against Clostridioides difficile infection. Bioorganic Chemistry 2022. [DOI: 10.1016/j.bioorg.2022.105843] [Reference Citation Analysis]
3 Amin A, Nelson WW, Dreyfus J, Wong AC, Mohammadi I, Teigland C, Dahdal DN, Feuerstadt P. Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with Clostridioides difficile infection with and without sepsis. Therapeutic Advances in Infection 2022;9:204993612210956. [DOI: 10.1177/20499361221095679] [Reference Citation Analysis]
4 Chen Y, Lv T, Yan D, Zheng L, Zheng B, Wang J, Gu S, Li L. Disordered Intestinal Microbial Communities During Clostridioides difficile Colonization and Subsequent Infection of Hepatic Cirrhosis Patients in a Tertiary Care Hospital in China. Front Cell Infect Microbiol 2022;12:825189. [DOI: 10.3389/fcimb.2022.825189] [Reference Citation Analysis]
5 Peery AF, Crockett SD, Murphy CC, Jensen ET, Kim HP, Egberg MD, Lund JL, Moon AM, Pate V, Barnes EL, Schlusser CL, Baron TH, Shaheen NJ, Sandler RS. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021. Gastroenterology 2021:S0016-5085(21)03655-6. [PMID: 34678215 DOI: 10.1053/j.gastro.2021.10.017] [Reference Citation Analysis]
6 Touchette MH, Benito de la Puebla H, Alves Feliciano C, Tanenbaum B, Schenone M, Carr SA, Shen A. Identification of a Novel Regulator of Clostridioides difficile Cortex Formation. mSphere 2021;6:e0021121. [PMID: 34047655 DOI: 10.1128/mSphere.00211-21] [Reference Citation Analysis]
7 Jenior ML, Papin JA. Computational approaches to understanding Clostridioides difficile metabolism and virulence. Curr Opin Microbiol 2021;65:108-15. [PMID: 34839237 DOI: 10.1016/j.mib.2021.11.002] [Reference Citation Analysis]
8 Yang Z, Huang Q, Qin J, Zhang X, Jian Y, Lv H, Liu Q, Li M. Molecular Epidemiology and Risk Factors of Clostridium difficile ST81 Infection in a Teaching Hospital in Eastern China. Front Cell Infect Microbiol 2020;10:578098. [PMID: 33425775 DOI: 10.3389/fcimb.2020.578098] [Reference Citation Analysis]
9 Kullar R, Tran MN, Goldstein EJC. Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI). J Exp Pharmacol 2020;12:371-84. [PMID: 33116952 DOI: 10.2147/JEP.S242959] [Reference Citation Analysis]
10 Chiu CH, Tsai MC, Cheng HT, Le PH, Kuo CJ, Chiu CT. Fecal microbiota transplantation and donor screening for Clostridioides difficile infection during COVID-19 pandemic. J Formos Med Assoc 2021;120:791-3. [PMID: 32713786 DOI: 10.1016/j.jfma.2020.07.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Alonso CD, Maron G, Kamboj M, Carpenter PA, Gurunathan A, Mullane K, Dubberke ER. American Society for Transplantation and Cellular Therapy Series: #5 - Management of Clostridioides difficile infection in hematopoietic cell transplant recipients. Transplant Cell Ther 2022:S2666-6367(22)00093-8. [PMID: 35202891 DOI: 10.1016/j.jtct.2022.02.013] [Reference Citation Analysis]
12 Fu Y, Luo Y, Grinspan AM. Epidemiology of community-acquired and recurrent Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211016248. [PMID: 34093740 DOI: 10.1177/17562848211016248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Solanki D, Kichloo A, El-Amir Z, Dahiya DS, Singh J, Wani F, Solanki S. Clostridium difficile Infection Hospitalizations in the United States: Insights From the 2017 National Inpatient Sample. Gastroenterology Res 2021;14:87-95. [PMID: 34007350 DOI: 10.14740/gr1371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Guilleman MM, Stevens BAY, Van Lieshout LP, Rghei AD, Pei Y, Santry LA, Thompson B, Wootton SK. AAV-mediated delivery of actoxumab and bezlotoxumab results in serum and mucosal antibody concentrations that provide protection from C. difficile toxin challenge. Gene Ther 2021. [PMID: 33608675 DOI: 10.1038/s41434-021-00236-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Ojha SC, Phanchana M, Harnvoravongchai P, Chankhamhaengdecha S, Singhakaew S, Ounjai P, Janvilisri T. Teicoplanin Suppresses Vegetative Clostridioides difficile and Spore Outgrowth. Antibiotics (Basel) 2021;10:984. [PMID: 34439034 DOI: 10.3390/antibiotics10080984] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Guo CLT, Kwong TNY, Mak JWY, Zhang L, Lui GCY, Wong GLH, Ip M, Yu J, Sung JJY, Wu WKK, Wong SH. Trends in Incidence and Clinical Outcomes of Clostridioides difficile Infection, Hong Kong. Emerg Infect Dis 2021;27. [PMID: 34812719 DOI: 10.3201/eid2712.203769] [Reference Citation Analysis]
17 Páramo-Zunzunegui J, Ortega-Fernández I, Calvo-Espino P, Diego-Hernández C, Ariza-Ibarra I, Otazu-Canals L, Danés-Grases JE, Menchero-Sánchez A. Severe Clostridium difficile colitis as potential late complication associated with COVID-19. Ann R Coll Surg Engl 2020;102:e176-9. [PMID: 32803988 DOI: 10.1308/rcsann.2020.0166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yun JH, Park GE, Ki HK. Correlation between antibiotic consumption and the incidence of healthcare facility-onset Clostridioides difficile infection: a retrospective chart review and analysis. Antimicrob Resist Infect Control 2021;10:117. [PMID: 34362442 DOI: 10.1186/s13756-021-00986-9] [Reference Citation Analysis]
19 Pike CM, Theriot CM. Mechanisms of Colonization Resistance Against Clostridioides difficile. J Infect Dis 2021;223:S194-200. [PMID: 33326565 DOI: 10.1093/infdis/jiaa408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Wendt S, Ranft D, Rodloff AC, Lippmann N, Lübbert C. Switching From Ceftriaxone to Cefotaxime Significantly Contributes to Reducing the Burden of Clostridioides difficile infections. Open Forum Infect Dis 2020;7:ofaa312. [PMID: 33005693 DOI: 10.1093/ofid/ofaa312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Khader K, Munoz-Price LS, Hanson R, Stevens V, Keegan LT, Thomas A, Pezzin LE, Nattinger A, Singh S, Samore MH. Transmission Dynamics of Clostridioides difficile in 2 High-Acuity Hospital Units. Clin Infect Dis 2021;72:S1-7. [PMID: 33512524 DOI: 10.1093/cid/ciaa1580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Kumar A, Ghazanfar H, Davidson JM. A Rare Case of Arterial and Venous Thromboembolism in a Patient With Severe Clostridium difficile Infection. Cureus 2021;13:e16103. [PMID: 34258130 DOI: 10.7759/cureus.16103] [Reference Citation Analysis]
23 Zaver HB, Moktan VP, Harper EP, Bali A, Nasir A, Foulks C, Kuhlman J, Green M, Algan GA, Parth HC, Wu-Ballis M, DiCicco S, Smith BT, Owen RN, Mai LS, Spiros SL, Griffis J, Ramsey Walker DT, Hata DJ, Oring JM, Powers HR, Bosch W. Reduction in Health Care Facility-Onset Clostridioides difficile Infection: A Quality Improvement Initiative. Mayo Clin Proc Innov Qual Outcomes 2021;5:1066-74. [PMID: 34820598 DOI: 10.1016/j.mayocpiqo.2021.09.004] [Reference Citation Analysis]
24 Gupta S, Allegretti JR. Mimics of Crohn's Disease. Gastroenterology Clinics of North America 2022. [DOI: 10.1016/j.gtc.2021.12.006] [Reference Citation Analysis]
25 Yu H, Flaster N, Casanello AL, Curcio D. Assessing risk factors, mortality, and healthcare utilization associated with Clostridioides difficile infection in four Latin American countries. Braz J Infect Dis 2021;25:101040. [PMID: 33290727 DOI: 10.1016/j.bjid.2020.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Khanna S. Management of Clostridioides difficile infection in patients with inflammatory bowel disease. Intest Res 2021;19:265-74. [PMID: 32806873 DOI: 10.5217/ir.2020.00045] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Zhou J, Horton JR, Yu D, Ren R, Blumenthal RM, Zhang X, Cheng X. Repurposing epigenetic inhibitors to target the Clostridioides difficile-specific DNA adenine methyltransferase and sporulation regulator CamA. Epigenetics 2021;:1-12. [PMID: 34523387 DOI: 10.1080/15592294.2021.1976910] [Reference Citation Analysis]
28 Dudzicz S, Wiecek A, Adamczak M. Clostridioides difficile Infection in Chronic Kidney Disease-An Overview for Clinicians. J Clin Med 2021;10:E196. [PMID: 33430465 DOI: 10.3390/jcm10020196] [Reference Citation Analysis]
29 Varga A, Kocsis B, Sipos D, Kása P, Vigvári S, Pál S, Dembrovszky F, Farkas K, Péterfi Z. How to Apply FMT More Effectively, Conveniently and Flexible - A Comparison of FMT Methods. Front Cell Infect Microbiol 2021;11:657320. [PMID: 34150673 DOI: 10.3389/fcimb.2021.657320] [Reference Citation Analysis]
30 Fishbein SRS, Hink T, Reske KA, Cass C, Struttmann E, Iqbal ZH, Seiler S, Kwon JH, Burnham CA, Dantas G, Dubberke ER. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients. mSphere 2021;6:e00936-20. [PMID: 33441409 DOI: 10.1128/mSphere.00936-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
31 De-la-rosa-martinez D, Rivera-buendía F, Cornejo-juárez P, García-pineda B, Nevárez-luján C, Vilar-compte D. Risk factors and clinical outcomes for Clostridioides difficile infections in a case control study at a large cancer referral center in Mexico. American Journal of Infection Control 2022. [DOI: 10.1016/j.ajic.2022.02.011] [Reference Citation Analysis]
32 Ghia CJ, Waghela S, Rambhad GS. Systematic Literature Review on Burden of Clostridioides difficile Infection in India. Clin Pathol 2021;14:2632010X211013816. [PMID: 34104883 DOI: 10.1177/2632010X211013816] [Reference Citation Analysis]
33 Mullish BH, Allegretti JR. The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211017725. [PMID: 34104212 DOI: 10.1177/17562848211017725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Allegretti JR, Nije C, McClure E, Redd WD, Wong D, Zhou JC, Bazarbashi AN, McCarty TR, Hathorn KE, Shen L, Jajoo K, Chan WW. Prevalence and impact of Clostridioides difficile infection among hospitalized patients with coranavirus disease 2019. JGH Open 2021;5:622-5. [PMID: 34013064 DOI: 10.1002/jgh3.12497] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
35 Gonzales-luna AJ, Carlson TJ. Follow your Gut: Microbiome-Based Approaches in the Developmental Pipeline for the Prevention and Adjunctive Treatment of Clostridioides difficile Infection (CDI). Curr Infect Dis Rep 2020;22. [DOI: 10.1007/s11908-020-00729-8] [Reference Citation Analysis]
36 McFarland LV. When It's Too Trying for Trials: A Commentary on a Different Approach for Testing a Probiotic, Saccharomyces boulardii, to Prevent Healthcare-associated Clostridioides difficile Infections. Clin Infect Dis 2021;73:e2519-20. [PMID: 32566936 DOI: 10.1093/cid/ciaa798] [Reference Citation Analysis]
37 Imwattana K, Putsathit P, Collins DA, Leepattarakit T, Kiratisin P, Riley TV, Knight DR. Global evolutionary dynamics and resistome analysis of Clostridioides difficile ribotype 017. Microb Genom 2022;8. [PMID: 35316173 DOI: 10.1099/mgen.0.000792] [Reference Citation Analysis]
38 Lalani F, Young EH, Panchal RM, Reveles KR. GABAergic but not Antidepressant Medications Increase Risk for Clostridioides difficile Infection in a National Cohort of Veterans. Open Forum Infect Dis 2020;7:ofaa353. [PMID: 32939356 DOI: 10.1093/ofid/ofaa353] [Reference Citation Analysis]
39 Sood G, Truelove S, Dougherty G, Landrum BM, Qasba S, Patel M, Miller A, Wilson C, Martin J, Sears C, Schuster A, Sulkowski M, Bennett R, Galai N. Clostridioides difficile infection (CDI) in a previous room occupant predicts CDI in subsequent room occupants across different hospital settings. Am J Infect Control 2022:S0196-6553(22)00079-7. [PMID: 35217092 DOI: 10.1016/j.ajic.2022.02.006] [Reference Citation Analysis]
40 Wu X, Shen WJ, Deshpande A, Olaitan AO, Palmer KL, Garey KW, Hurdle JG. The Integrity of Heme Is Essential for Reproducible Detection of Metronidazole-Resistant Clostridioides difficile by Agar Dilution Susceptibility Tests. J Clin Microbiol 2021;59:e0058521. [PMID: 34132582 DOI: 10.1128/JCM.00585-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Carlson TJ, Gonzales-Luna AJ, Garey KW. Fulminant Clostridioides difficile Infection: A Review of Treatment Options for a Life-Threatening Infection. Semin Respir Crit Care Med 2022;43:28-38. [PMID: 35172356 DOI: 10.1055/s-0041-1740973] [Reference Citation Analysis]
42 Chen Y, Xi M, Johnson A, Tomlinson G, Campigotto A, Chen L, Sung L. Machine Learning Approaches to Investigate Clostridioides difficile Infection and Outcomes: A Systematic Review. International Journal of Medical Informatics 2022. [DOI: 10.1016/j.ijmedinf.2022.104706] [Reference Citation Analysis]
43 Ali H, Khurana S, Ma W, Peng Y, Jiang ZD, DuPont H, Zhang HC, Thomas AS, Okhuysen P, Wang Y. Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent Clostridioides difficile in cancer patients. J Cancer 2021;12:6498-506. [PMID: 34659541 DOI: 10.7150/jca.59251] [Reference Citation Analysis]
44 Blumberg EA, Collins G, Young JH, Nguyen MH, Michonneau D, Temesgen Z, Origȕen J, Barcan L, Obeid KM, Belloso WH, Gras J, Corbelli GM, Neaton JD, Lundgren J, Snydman DR, Molina JM; INSIGHT Clostridioides difficile Study Group. Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study. Transpl Infect Dis 2021;:e13770. [PMID: 34821423 DOI: 10.1111/tid.13770] [Reference Citation Analysis]
45 Sheikh AAE, Sheikh AB, Shah I, Khair AH, Javed N, Shekhar R. COVID-19 and Fulminant Clostridium difficile Colitis Co-Infection. Eur J Case Rep Intern Med 2021;8:002771. [PMID: 34527627 DOI: 10.12890/2021_002771] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Sandhu A, Tillotson G, Polistico J, Salimnia H, Cranis M, Moshos J, Cullen L, Jabbo L, Diebel L, Chopra T. Clostridioides difficile in COVID-19 Patients, Detroit, Michigan, USA, March-April 2020. Emerg Infect Dis 2020;26. [PMID: 32441243 DOI: 10.3201/eid2609.202126] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 12.0] [Reference Citation Analysis]
47 Kullar R, Johnson S, McFarland LV, Goldstein EJC. Potential Roles for Probiotics in the Treatment of COVID-19 Patients and Prevention of Complications Associated with Increased Antibiotic Use. Antibiotics (Basel) 2021;10:408. [PMID: 33918619 DOI: 10.3390/antibiotics10040408] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Hong S, Putsathit P, George N, Hemphill C, Huntington PG, Korman TM, Kotsanas D, Lahra M, McDougall R, Moore CV, Nimmo GR, Prendergast L, Robson J, Waring L, Wehrhahn MC, Weldhagen GF, Wilson RM, Riley TV, Knight DR. Laboratory-Based Surveillance of Clostridium difficile Infection in Australian Health Care and Community Settings, 2013 to 2018. J Clin Microbiol 2020;58:e01552-20. [PMID: 32848038 DOI: 10.1128/JCM.01552-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Haider A, Alavi F, Siddiqa A, Abbas H, Patel H. Fulminant Pseudomembranous Colitis Leading to Clostridium Paraputrificum Bacteremia. Cureus 2021;13:e13763. [PMID: 33842139 DOI: 10.7759/cureus.13763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Scaria E, Powell WR, Birstler J, Alagoz O, Shirley D, Kind AJH, Safdar N. Neighborhood disadvantage and 30-day readmission risk following Clostridioides difficile infection hospitalization. BMC Infect Dis 2020;20:762. [PMID: 33066737 DOI: 10.1186/s12879-020-05481-x] [Reference Citation Analysis]
51 Ressler A, Wang J, Rao K. Defining the black box: a narrative review of factors associated with adverse outcomes from severe Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211048127. [PMID: 34646358 DOI: 10.1177/17562848211048127] [Reference Citation Analysis]
52 Kampouri E, Croxatto A, Prod'hom G, Guery B. Clostridioides difficile Infection, Still a Long Way to Go. J Clin Med 2021;10:389. [PMID: 33498428 DOI: 10.3390/jcm10030389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
53 Shaikh DH, Patel H, Munshi R, Sun H, Mehershahi S, Baiomi A, Alemam A, Pirzada U, Nawaz I, Naher K, Hanumanthu S, Nayudu S. Patients with Clostridium difficile infection and prior appendectomy may be prone to worse outcomes. World J Gastrointest Surg 2021; 13(11): 1436-1447 [DOI: 10.4240/wjgs.v13.i11.1436] [Reference Citation Analysis]
54 Alrawashdeh M, Rhee C, Hsu H, Wang R, Horan K, Lee GM. Assessment of Federal Value-Based Incentive Programs and In-Hospital Clostridioides difficile Infection Rates. JAMA Netw Open 2021;4:e2132114. [PMID: 34714336 DOI: 10.1001/jamanetworkopen.2021.32114] [Reference Citation Analysis]
55 Chen P, Jin R. Receptor binding mechanisms of Clostridioides difficile toxin B and implications for therapeutics development. FEBS J 2021. [PMID: 34862749 DOI: 10.1111/febs.16310] [Reference Citation Analysis]
56 Chen J, Zaman A, Ramakrishna B, Olesen SW. Stool Banking for Fecal Microbiota Transplantation: Methods and Operations at a Large Stool Bank. Front Cell Infect Microbiol 2021;11:622949. [PMID: 33937092 DOI: 10.3389/fcimb.2021.622949] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
57 Qian Y, Lan F, Venturelli OS. Towards a deeper understanding of microbial communities: integrating experimental data with dynamic models. Curr Opin Microbiol 2021;62:84-92. [PMID: 34098512 DOI: 10.1016/j.mib.2021.05.003] [Reference Citation Analysis]
58 Obaid NA, Alhifany AA. Clostridioides difficile infections in Saudi Arabia: Where are we standing? Saudi Pharm J 2020;28:1118-21. [PMID: 32922143 DOI: 10.1016/j.jsps.2020.07.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Orenstein R, Dubberke ER, Khanna S, Lee CH, Yoho D, Johnson S, Hecht G, Dupont HL, Gerding DN, Blount KF, Mische S, Harvey A. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07256-y] [Reference Citation Analysis]
60 Khanna S, Pardi R. Clostridioides difficile infection: curbing a difficult menace. Therap Adv Gastroenterol 2022;15:175628482210899. [DOI: 10.1177/17562848221089906] [Reference Citation Analysis]
61 Scaria E, Barker AK, Alagoz O, Safdar N. Association of Visitor Contact Precautions With Estimated Hospital-Onset Clostridioides difficile Infection Rates in Acute Care Hospitals. JAMA Netw Open 2021;4:e210361. [PMID: 33635330 DOI: 10.1001/jamanetworkopen.2021.0361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Labajová N, Baranova N, Jurásek M, Vácha R, Loose M, Barák I. Cardiolipin-Containing Lipid Membranes Attract the Bacterial Cell Division Protein DivIVA. Int J Mol Sci 2021;22:8350. [PMID: 34361115 DOI: 10.3390/ijms22158350] [Reference Citation Analysis]
63 Maslanka JR, Gu CH, Zarin I, Denny JE, Broadaway S, Fett B, Mattei LM, Walk ST, Abt MC. Detection and elimination of a novel non-toxigenic Clostridioides difficile strain from the microbiota of a mouse colony. Gut Microbes 2020;12:1-15. [PMID: 33305657 DOI: 10.1080/19490976.2020.1851999] [Reference Citation Analysis]
64 Carlson TJ, Gonzales-luna AJ. Antibiotic Treatment Pipeline for Clostridioides difficile Infection (CDI): A Wide Array of Narrow-Spectrum Agents. Curr Infect Dis Rep 2020;22. [DOI: 10.1007/s11908-020-00730-1] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Adelman MW, Goodenough D, Sefton S, Mackey C, Thomas S, Fridkin SK, Woodworth MH. Changes in treatment of community-onset Clostridioides difficile infection after release of updated guidelines, Atlanta, Georgia, 2018. Anaerobe 2021;70:102364. [PMID: 33862203 DOI: 10.1016/j.anaerobe.2021.102364] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Simmons S, Wier G, Pedraza A, Stibich M. Impact of a pulsed xenon disinfection system on hospital onset Clostridioides difficile infections in 48 hospitals over a 5-year period. BMC Infect Dis 2021;21:1084. [PMID: 34670520 DOI: 10.1186/s12879-021-06789-y] [Reference Citation Analysis]
67 Sandhu A, Chopra T. Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls. Therap Adv Gastroenterol 2021;14:17562848211053105. [PMID: 34992678 DOI: 10.1177/17562848211053105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Sprague R, Warny K, Pollock N, Daugherty K, Lin Q, Xu H, Cuddemi C, Barrett C, Chen X, Banz A, Lantz A, Garey KW, Gonzales-Luna AJ, Alonso CD, Galvez JAV, Kelly CP. Absence of Toxemia in Clostridioides difficile Infection: Results from Ultrasensitive Toxin Assay of Serum. Dig Dis Sci 2021;66:3303-6. [PMID: 33164145 DOI: 10.1007/s10620-020-06683-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
69 Gupta A, Ananthakrishnan AN. Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review. Therap Adv Gastroenterol 2021;14:17562848211018654. [PMID: 34104214 DOI: 10.1177/17562848211018654] [Reference Citation Analysis]
70 Lee HS, Plechot K, Gohil S, Le J. Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis. Infect Dis Ther 2021;10:687-97. [PMID: 33770398 DOI: 10.1007/s40121-021-00417-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
71 Deshpande A, Wu X, Huo W, Palmer KL, Hurdle JG. Chromosomal Resistance to Metronidazole in Clostridioides difficile Can Be Mediated by Epistasis between Iron Homeostasis and Oxidoreductases. Antimicrob Agents Chemother 2020;64:e00415-20. [PMID: 32457109 DOI: 10.1128/AAC.00415-20] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
72 Gonzales-Luna AJ, Spinler JK, Oezguen N, Khan MAW, Danhof HA, Endres BT, Alam MJ, Begum K, Lancaster C, Costa GP, Savidge TC, Hurdle JG, Britton R, Garey KW. Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation. Anaerobe 2021;70:102387. [PMID: 34044101 DOI: 10.1016/j.anaerobe.2021.102387] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Roberts AK, Harris HC, Smith M, Giles J, Polak O, Buckley AM, Clark E, Ewin D, Moura IB, Spitall W, Shone CC, Wilcox M, Chilton C, Donev R. A Novel, Orally Delivered Antibody Therapy and Its Potential to Prevent Clostridioides difficile Infection in Pre-clinical Models. Front Microbiol 2020;11:578903. [PMID: 33072047 DOI: 10.3389/fmicb.2020.578903] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
74 Feuerstadt P, Boules M, Stong L, Dahdal DN, Sacks NC, Lang K, Nelson WW. Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis. SAGE Open Med 2021;9:2050312120986733. [PMID: 33505698 DOI: 10.1177/2050312120986733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Khanna S, Pardi DS, Jones C, Shannon WD, Gonzalez C, Blount K. RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections. Clin Infect Dis 2021;73:e1613-20. [PMID: 32966574 DOI: 10.1093/cid/ciaa1430] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
76 Benitez G, Shehadeh F, Kalligeros M, Mylona EK, Tran Q, Zacharioudakis IM, Mylonakis E. Risk Factors for Hospital Readmission for Clostridioides difficile Infection: A Statewide Retrospective Cohort Study. Pathogens 2022;11:555. [DOI: 10.3390/pathogens11050555] [Reference Citation Analysis]
77 Łukawska A, Mulak A. Impact of Primary and Secondary Bile Acids on Clostridioides difficile Infection. Polish Journal of Microbiology 2022;0. [DOI: 10.33073/pjm-2022-007] [Reference Citation Analysis]
78 Richards AR, Linder JA. Behavioral Economics and Ambulatory Antibiotic Stewardship: A Narrative Review. Clin Ther 2021;43:1654-67. [PMID: 34702589 DOI: 10.1016/j.clinthera.2021.08.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Townsend SR. Antibiotic Administration and Timing: Risks, Delay, Zombies. Crit Care Med 2021;49:1818-21. [PMID: 34529613 DOI: 10.1097/CCM.0000000000005151] [Reference Citation Analysis]
80 Littmann ER, Lee JJ, Denny JE, Alam Z, Maslanka JR, Zarin I, Matsuda R, Carter RA, Susac B, Saffern MS, Fett B, Mattei LM, Bittinger K, Abt MC. Host immunity modulates the efficacy of microbiota transplantation for treatment of Clostridioides difficile infection. Nat Commun 2021;12:755. [PMID: 33531483 DOI: 10.1038/s41467-020-20793-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
81 Panchavati S, Zelin NS, Garikipati A, Pellegrini E, Iqbal Z, Barnes G, Hoffman J, Calvert J, Mao Q, Das R. A comparative analysis of machine learning approaches to predict C. difficile infection in hospitalized patients. American Journal of Infection Control 2022. [DOI: 10.1016/j.ajic.2021.11.012] [Reference Citation Analysis]
82 Walter C, Soni T, Gavin MA, Kubes J, Paciullo K. An interprofessional approach to reducing hospital-onset Clostridioides difficile infections. American Journal of Infection Control 2022. [DOI: 10.1016/j.ajic.2022.02.017] [Reference Citation Analysis]
83 Hengel RL, Schroeder CP, Jo J, Ritter TE, Nathan RV, Gonzales-Luna AJ, Obi EN, Dillon RJ, Van Anglen LJ, Garey KW. Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life. J Patient Rep Outcomes 2022;6:49. [PMID: 35567724 DOI: 10.1186/s41687-022-00456-9] [Reference Citation Analysis]
84 Alonso CD, Papamichael K, Sprague R, Barrett C, Gonzales-Luna AJ, Daugherty K, Garey KW, Villafuerte-Gálvez J, Xu H, Lin Q, Wang L, Chen X, Pollock NR, Kelly CP. Humoral Immune Response to Clostridioides difficile Toxins A and B in Hospitalized Immunocompromised Patients With C difficile Infection. Open Forum Infect Dis 2021;8:ofab286. [PMID: 34258317 DOI: 10.1093/ofid/ofab286] [Reference Citation Analysis]
85 Vedala K, Sobash P, Shah P, Kamoga GR. Does Fecal Microbiota Transplant Have a Role in Treating Recurrent Clostridioides difficile Infection in Rural Hospitals? Front Public Health 2021;9:670941. [PMID: 34178927 DOI: 10.3389/fpubh.2021.670941] [Reference Citation Analysis]
86 O'Neal M, Murray H, Dash S, Al-Hasan MN, Justo JA, Bookstaver PB. Evaluating appropriateness and diagnostic stewardship opportunities of multiplex polymerase chain reaction gastrointestinal testing within a hospital system. Ther Adv Infect Dis 2020;7:2049936120959561. [PMID: 33014363 DOI: 10.1177/2049936120959561] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
87 Hosseini-Moghaddam SM, Luo B, Bota SE, Husain S, Silverman MS, Daneman N, Brown KA, Paterson JM. Incidence and Outcomes Associated With Clostridioides difficile Infection in Solid Organ Transplant Recipients. JAMA Netw Open 2021;4:e2141089. [PMID: 34964852 DOI: 10.1001/jamanetworkopen.2021.41089] [Reference Citation Analysis]
88 Schwenk HT, Pollock NR, Vaughan-Malloy AM. Pediatric Clostridioides difficile Infection: Diagnosis and Diagnostic Stewardship. J Pediatric Infect Dis Soc 2021;10:S16-21. [PMID: 34791395 DOI: 10.1093/jpids/piab054] [Reference Citation Analysis]
89 Mondal SI, Draper LA, Ross RP, Hill C. Bacteriophage endolysins as a potential weapon to combat Clostridioides difficile infection. Gut Microbes 2020;12:1813533. [PMID: 32985336 DOI: 10.1080/19490976.2020.1813533] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
90 Mondal SI, Akter A, Draper LA, Ross RP, Hill C. Characterization of an Endolysin Targeting Clostridioides difficile That Affects Spore Outgrowth. Int J Mol Sci 2021;22:5690. [PMID: 34073633 DOI: 10.3390/ijms22115690] [Reference Citation Analysis]
91 Marreddy RKR, Olaitan AO, May JN, Dong M, Hurdle JG. Ebselen Not Only Inhibits Clostridioides difficile Toxins but Displays Redox-Associated Cellular Killing. Microbiol Spectr 2021;9:e0044821. [PMID: 34468187 DOI: 10.1128/Spectrum.00448-21] [Reference Citation Analysis]
92 Al Moussawi H, Alsheikh M, Kamar K, Awada Z, Hosry J, Deeb L. Beyond Pain Relief: Is Opioids Use Safe in Clostridium difficile Infection? Gastroenterology Res 2021;14:275-80. [PMID: 34804271 DOI: 10.14740/gr1453] [Reference Citation Analysis]
93 Feuerstadt P, Nelson WW, Drozd EM, Dreyfus J, Dahdal DN, Wong AC, Mohammadi I, Teigland C, Amin A. Mortality, Health Care Use, and Costs of Clostridioides difficile Infections in Older Adults. Journal of the American Medical Directors Association 2022. [DOI: 10.1016/j.jamda.2022.01.075] [Reference Citation Analysis]
94 Cribas ES, Denny JE, Maslanka JR, Abt MC. Loss of Interleukin-10 (IL-10) Signaling Promotes IL-22-Dependent Host Defenses against Acute Clostridioides difficile Infection. Infect Immun 2021;89:e00730-20. [PMID: 33649048 DOI: 10.1128/IAI.00730-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
95 Khanna S, Lett J, Lattimer C, Tillotson G. Transitions of care in Clostridioides difficile infection: a need of the hour. Therap Adv Gastroenterol 2022;15:175628482210786. [DOI: 10.1177/17562848221078684] [Reference Citation Analysis]
96 Chen P, Zeng J, Liu Z, Thaker H, Wang S, Tian S, Zhang J, Tao L, Gutierrez CB, Xing L, Gerhard R, Huang L, Dong M, Jin R. Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection. Nat Commun 2021;12:3748. [PMID: 34145250 DOI: 10.1038/s41467-021-23878-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Knight DR, Imwattana K, Kullin B, Guerrero-Araya E, Paredes-Sabja D, Didelot X, Dingle KE, Eyre DW, Rodríguez C, Riley TV. Major genetic discontinuity and novel toxigenic species in Clostridioides difficile taxonomy. Elife 2021;10:e64325. [PMID: 34114561 DOI: 10.7554/eLife.64325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
98 Li J, Zhang Y, Jilg AL, Wolk DM, Khara HS, Kolinovsky A, Rolston DDK, Hontecillas R, Bassaganya-Riera J, Williams MS, Abedi V, Lee MTM. Variants at the MHC Region Associate With Susceptibility to Clostridioides difficile Infection: A Genome-Wide Association Study Using Comprehensive Electronic Health Records. Front Immunol 2021;12:638913. [PMID: 33841421 DOI: 10.3389/fimmu.2021.638913] [Reference Citation Analysis]
99 Mehta SR, Yen EF. Microbiota-based Therapies Clostridioides difficile infection that is refractory to antibiotic therapy. Transl Res 2021;230:197-207. [PMID: 33278650 DOI: 10.1016/j.trsl.2020.11.013] [Reference Citation Analysis]
100 Singh SB, Miesel L, Kramer S, Xu L, Li F, Lan J, Lipari P, Polishook JD, Liu G, Liang L, Flattery AM. Nocathiacin, Thiazomycin, and Polar Analogs Are Highly Effective Agents against Toxigenic Clostridioides difficile. J Nat Prod 2022. [PMID: 35380836 DOI: 10.1021/acs.jnatprod.2c00093] [Reference Citation Analysis]
101 Chaar A, Feuerstadt P. Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211011953. [PMID: 33995583 DOI: 10.1177/17562848211011953] [Reference Citation Analysis]
102 Purcell EB. Second messenger signaling in Clostridioides difficile. Curr Opin Microbiol 2021;65:138-44. [PMID: 34864551 DOI: 10.1016/j.mib.2021.11.006] [Reference Citation Analysis]
103 Sehgal K, Khanna S. Immune response against Clostridioides difficile and translation to therapy. Therap Adv Gastroenterol 2021;14:17562848211014817. [PMID: 33995585 DOI: 10.1177/17562848211014817] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Buehrle D, Clancy CJ. Medicare Prescription Plans Limit Access to Recommended Drugs for Clostridioides difficile Infection. Clin Infect Dis 2021:ciab898. [PMID: 34626478 DOI: 10.1093/cid/ciab898] [Reference Citation Analysis]
105 Gonzales-Luna AJ, Olaitan AO, Shen WJ, Deshpande A, Carlson TJ, Dotson KM, Lancaster C, Begum K, Alam MJ, Hurdle JG, Garey KW. Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection. Open Forum Infect Dis 2021;8:ofab365. [PMID: 34381844 DOI: 10.1093/ofid/ofab365] [Reference Citation Analysis]
106 Fishbein SR, Robinson JI, Hink T, Reske KA, Newcomer EP, Burnham CD, Henderson JP, Dubberke ER, Dantas G. Multi-omics investigation of Clostridioides difficile-colonized patients reveals pathogen and commensal correlates of C. difficile pathogenesis. Elife 2022;11:e72801. [PMID: 35083969 DOI: 10.7554/eLife.72801] [Reference Citation Analysis]
107 Morales-Marroquin E, Xie L, Uppuluri M, Almandoz JP, Cruz-Muñoz N, Messiah SE. Immunosuppression and Clostridioides (Clostridium) difficile Infection Risk in Metabolic and Bariatric Surgery Patients. J Am Coll Surg 2021;233:223-31. [PMID: 34015452 DOI: 10.1016/j.jamcollsurg.2021.04.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Poudel A, Pokhrel A, Oludiran A, Coronado EJ, Alleyne K, Gilfus MM, Gurung RK, Adhikari SB, Purcell EB. Unique Features of Alarmone Metabolism in Clostridioides difficile. J Bacteriol 2022;:e0057521. [PMID: 35254095 DOI: 10.1128/jb.00575-21] [Reference Citation Analysis]
109 Skinner AM, Scardina T, Kociolek LK. Fidaxomicin for the treatment of Clostridioides difficile in children. Future Microbiol 2020;15:967-79. [PMID: 32715754 DOI: 10.2217/fmb-2020-0104] [Reference Citation Analysis]
110 Kordus SL, Thomas AK, Lacy DB. Clostridioides difficile toxins: mechanisms of action and antitoxin therapeutics. Nat Rev Microbiol 2021. [PMID: 34837014 DOI: 10.1038/s41579-021-00660-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Mansfield MJ, Tremblay BJ, Zeng J, Wei X, Hodgins H, Worley J, Bry L, Dong M, Doxey AC. Phylogenomics of 8,839 Clostridioides difficile genomes reveals recombination-driven evolution and diversification of toxin A and B. PLoS Pathog 2020;16:e1009181. [PMID: 33370413 DOI: 10.1371/journal.ppat.1009181] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
112 Sugimoto H, Yoshihara A, Yamamoto T, Sugimoto K. A preliminary study of bowel rest strategy in the management of Clostridioides difficile infection. Sci Rep 2020;10:22061. [PMID: 33328505 DOI: 10.1038/s41598-020-79211-3] [Reference Citation Analysis]
113 Kim MH, Kim YC, Kim JL, Park YS, Kim H. Description of antibiotic treatment in adults tested for Clostridioides difficile infection: a single-center case–control study. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07085-z] [Reference Citation Analysis]
114 Petersen MR, Cosgrove SE, Klein EY, Zhu X, Quinn TC, Patel EU, Grabowski MK, Tobian AAR. Clostridioides difficile Prevalence in the United States: National Inpatient Sample, 2016 to 2018. Open Forum Infect Dis 2021;8:ofab409. [PMID: 34671694 DOI: 10.1093/ofid/ofab409] [Reference Citation Analysis]
115 Lanzas C, Jara M, Tucker R, Curtis S; CDC Modeling Infectious Diseases in Healthcare Program (MinD). A review of epidemiological models of Clostridioides difficile transmission and control (2009-2021). Anaerobe 2022;:102541. [PMID: 35217149 DOI: 10.1016/j.anaerobe.2022.102541] [Reference Citation Analysis]
116 Wang PW, Lee WT, Wu YN, Shieh DB. Opportunities for Nanomedicine in Clostridioides difficile Infection. Antibiotics (Basel) 2021;10:948. [PMID: 34438998 DOI: 10.3390/antibiotics10080948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Angulo FJ, Oliva SP, Carrico R, Furmanek S, Zamparo J, Gonzalez E, Gray S, Ford KD, Swerdlow D, Moïsi JC, Ramirez J. Frequency of stool specimen collection and testing for Clostridioides difficile of hospitalized adults and long-term care facility residents with new-onset diarrhea in Louisville, Kentucky. Int J Infect Dis 2022;120:196-200. [PMID: 35477052 DOI: 10.1016/j.ijid.2022.04.046] [Reference Citation Analysis]
118 Taggart MG, Snelling WJ, Naughton PJ, La Ragione RM, Dooley JSG, Ternan NG. Biofilm regulation in Clostridioides difficile: Novel systems linked to hypervirulence. PLoS Pathog 2021;17:e1009817. [PMID: 34499698 DOI: 10.1371/journal.ppat.1009817] [Reference Citation Analysis]